Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Agriculture/FDA Appropriations Likely to be Overtaken by a Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More Advocacy at a Glance STEVEN GROSSMAN 8/4/23 Advocacy at a Glance STEVEN GROSSMAN 8/4/23 Agriculture/FDA Appropriations in Limbo as End of Fiscal Year Looms Read More Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More Advocacy at a Glance STEVEN GROSSMAN 7/28/23 Advocacy at a Glance STEVEN GROSSMAN 7/28/23 Ag/FDA Appropriations Bill Does Not Move in the House – September Action Expected Read More Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More Advocacy at a Glance STEVEN GROSSMAN 7/21/23 Advocacy at a Glance STEVEN GROSSMAN 7/21/23 Floor Action on House Ag/FDA Appropriations Bill May Be Next Week Read More Advocacy at a Glance STEVEN GROSSMAN 7/14/23 Advocacy at a Glance STEVEN GROSSMAN 7/14/23 Further Appropriations Action Yet to be Scheduled Read More Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More Advocacy at a Glance STEVEN GROSSMAN 6/30/23 Advocacy at a Glance STEVEN GROSSMAN 6/30/23 The Alliance’s Priority: Resources Not Policy Read More Advocacy at a Glance STEVEN GROSSMAN 6/23/23 Advocacy at a Glance STEVEN GROSSMAN 6/23/23 Senate Appropriations Committee Approves $20 Million Increase for FDA Read More Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More
Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More
Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More
Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Agriculture/FDA Appropriations Likely to be Overtaken by a Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 8/25/23 Analysis and Commentary STEVEN GROSSMAN 8/25/23 Commissioner Califf Talks About AI Read More
Advocacy at a Glance STEVEN GROSSMAN 8/4/23 Advocacy at a Glance STEVEN GROSSMAN 8/4/23 Agriculture/FDA Appropriations in Limbo as End of Fiscal Year Looms Read More
Analysis and Commentary STEVEN GROSSMAN 8/4/23 Analysis and Commentary STEVEN GROSSMAN 8/4/23 FDA Funding Judged in Absolute and Relative Terms Read More
Advocacy at a Glance STEVEN GROSSMAN 7/28/23 Advocacy at a Glance STEVEN GROSSMAN 7/28/23 Ag/FDA Appropriations Bill Does Not Move in the House – September Action Expected Read More
Analysis and Commentary STEVEN GROSSMAN 7/28/23 Analysis and Commentary STEVEN GROSSMAN 7/28/23 FDA, Appropriations, and Chaos: The Risk of a Perfect Storm Read More
Analysis and Commentary STEVEN GROSSMAN 7/21/23 Analysis and Commentary STEVEN GROSSMAN 7/21/23 “FDA Brings Good Things to Life” Read More
Advocacy at a Glance STEVEN GROSSMAN 7/21/23 Advocacy at a Glance STEVEN GROSSMAN 7/21/23 Floor Action on House Ag/FDA Appropriations Bill May Be Next Week Read More
Advocacy at a Glance STEVEN GROSSMAN 7/14/23 Advocacy at a Glance STEVEN GROSSMAN 7/14/23 Further Appropriations Action Yet to be Scheduled Read More
Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More
Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More
Advocacy at a Glance STEVEN GROSSMAN 6/30/23 Advocacy at a Glance STEVEN GROSSMAN 6/30/23 The Alliance’s Priority: Resources Not Policy Read More
Advocacy at a Glance STEVEN GROSSMAN 6/23/23 Advocacy at a Glance STEVEN GROSSMAN 6/23/23 Senate Appropriations Committee Approves $20 Million Increase for FDA Read More
Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More
